Doxazosin Shortage: What Providers and Prescribers Need to Know in 2026

While doxazosin is not currently listed on the FDA's Drug Shortage Database, patients are increasingly reporting difficulty filling their prescriptions at individual pharmacies. As a prescriber, understanding the nuances of doxazosin's supply environment — and having a clear action plan for affected patients — can prevent care disruptions for your BPH and hypertension patients.

Current Supply Environment: No FDA Shortage, But Localized Gaps

As of 2026, doxazosin mesylate (immediate-release tablets: 1 mg, 2 mg, 4 mg, 8 mg) is not on the FDA's Drug Shortage list. Multiple generic manufacturers remain active in this market, providing supply redundancy. However, localized availability gaps persist due to:

Pharmacy-level inventory management and ordering cycles

Dosage-specific stockouts (particularly the less commonly ordered 1 mg and 2 mg strengths)

Extended-release Cardura XL unavailability (brand-only, fewer stockists)

Regional demand patterns in geriatric-heavy patient populations

Note: the extended-release formulation (Cardura XL) is more commonly subject to availability issues given its brand-only status and narrower distribution.

Clinical Considerations for Doxazosin Interruption

For patients on doxazosin for hypertension, abrupt discontinuation carries rebound hypertension risk. Unlike centrally-acting antihypertensives (clonidine) where discontinuation can cause hypertensive crisis, rebound with alpha-1 blockers is generally less dramatic — but blood pressure should be monitored carefully during any planned interruption.

For BPH-only patients, short interruptions are generally better tolerated clinically, though LUTS symptoms may worsen. Counsel patients accordingly if a brief supply gap is anticipated.

Therapeutic Substitution Options by Indication

For BPH + Hypertension (dual-indication patients):

Terazosin — closest clinical equivalent; FDA-approved for both BPH and hypertension; requires titration starting at 1 mg at bedtime; typically 2–10 mg once daily at max; generic only.

For BPH-only patients:

Tamsulosin 0.4 mg daily — most prescribed option; uroselective; no titration required; most patients tolerate well; generic widely available.

Alfuzosin 10 mg daily — no titration; well-tolerated; lower IFIS risk than tamsulosin; take with breakfast; generic available.

Silodosin 8 mg daily — highly uroselective; brand-only (Rapaflo); note higher rate of retrograde ejaculation (~28%); reserve for patients who need minimal cardiovascular effects.

For hypertension-only patients:

Current JNC 8 and AHA/ACC guidelines recommend alpha-1 blockers only as adjunctive therapy, not first-line, for uncomplicated hypertension (particularly based on ALLHAT data showing increased CHF risk with doxazosin vs. chlorthalidone). If a patient is on doxazosin solely for hypertension, this may be an appropriate time to transition to a guideline-preferred agent (ACE inhibitor, ARB, calcium channel blocker, or thiazide diuretic).

IFIS Risk Warning for All Alpha Blockers

Remind patients switching to any alpha blocker that intraoperative floppy iris syndrome (IFIS) risk persists after discontinuation of any alpha-1 blocker and may not resolve. Patients should disclose alpha-blocker use — current or past — to any ophthalmologist planning cataract or glaucoma surgery. Tamsulosin carries the highest published odds ratio for IFIS (OR = 393.1 in meta-analysis), but risk exists across the entire class.

Titration Requirements When Switching Between Alpha Blockers

When switching from doxazosin to terazosin:

Initiate terazosin at 1 mg at bedtime (not at the equivalent doxazosin dose)

Titrate every 1–2 weeks as tolerated

Monitor BP for orthostatic hypotension for 6 hours after each dose increase

Tamsulosin and alfuzosin do not require titration, which makes them operationally simpler for quick substitutions.

How medfinder Can Help Your Patients

Rather than having your staff spend time on hold with multiple pharmacies, consider directing patients to medfinder for providers. medfinder calls pharmacies near the patient's location to check which ones can fill their doxazosin prescription, then texts the results directly to the patient — reducing call volume to your office and getting patients their medication faster.

Documentation and Patient Communication Tips

Document the indication for doxazosin clearly (BPH, hypertension, or both) to facilitate faster substitution decisions if needed

Advise patients taking doxazosin for hypertension not to stop abruptly if a refill is delayed — contact the office

For patients on Cardura XL specifically, consider whether immediate-release generic doxazosin with twice-daily dosing (or a switch to tamsulosin for BPH-only) would provide equivalent clinical outcomes with better availability

For a practical workflow guide on helping patients locate their medication, see our companion article How to Help Your Patients Find Doxazosin in Stock: A Provider's Guide.